2026-01-04 - Analysis Report
Okay, here's a comprehensive report on Teladoc Health Inc. (TDOC) based on the data you provided, with simple numbers first, followed by analysis.

**1. Return Rate Comparison**

*   **Ticker:** TDOC
*   **Company Overview:** Teladoc Health Inc. is a telehealth company offering virtual medical care.
*   **TDOC Cumulative Return:** -64.46%
*   **VOO (S&P 500) Cumulative Return:** 91.00%
*   **Divergence:** -156.6 (Relative Divergence: 0.5)

**Analysis:** TDOC has significantly underperformed the S&P 500 (VOO) over the covered period. The divergence of -156.6 indicates a substantial gap in performance. The relative divergence of 0.5 suggests the current divergence is closer to the minimum seen historically within its fluctuation range, implying potentially less room for further decline based purely on historical divergence. The stock is currently trading at a price point that makes it attractive, but the numbers suggest a long-term underperformance with the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta | Cap(B) |
|------------|--------|-------|---------|------|--------|
| 2016-2018  | 74.0%  | 52.9% | 71.0%   | 1.7  | 8.8    |
| 2017-2019  | 119.0% | 52.9% | 101.0%  | 1.8  | 14.9   |
| 2018-2020  | 87.0%  | 52.9% | 66.0%   | 0.7  | 35.5   |
| 2019-2021  | -84.0% | 60.6% | -127.0% | 0.5  | 16.3   |
| 2020-2022  | -246.0%| 83.0% | -244.0% | 0.8  | 4.2    |
| 2021-2023  | -302.0%| 83.0% | -303.0% | 1.9  | 3.8    |
| 2022-2024  | -87.0% | 72.3% | -107.0% | 1.9  | 1.6    |
| 2023-2025  | -34.0% | 65.6% | -96.0%  | 1.7  | 1.2    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate shows wildly fluctuating performance.  Early periods (2016-2020) showed high growth, but more recent periods show significant declines.
*   **MDD:**  Maximum Drawdown is consistently high, indicating significant risk and volatility.
*   **Alpha:** Alpha is negative for most recent periods, indicating underperformance relative to its benchmark.
*   **Beta:** Beta fluctuates, but is generally above 1.0, suggesting the stock is more volatile than the market. It looks like the stock is being less volatile, but with negative Alpha values.
*   **Cap(B):**  Market capitalization is decreasing over time, suggesting the company's value is declining.

**2. Recent Stock Price Fluctuations**

*   **Close:** 7.05
*   **Last Market:** Price: 7.05, Previous Close: 7.0, Change: 0.71
*   **5-day SMA:** 7.02
*   **20-day SMA:** 7.334
*   **60-day SMA:** 7.7648

**Analysis:** The current price (7.05) is below all three Simple Moving Averages (SMA). This suggests a short-term and medium-term downtrend. The price is slightly higher than the 5-day SMA, indicating a possible very short-term stabilization or slight upward momentum.

**3. RSI, PPO and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 27.56
*   **PPO:** -0.3152
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (133 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.5 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -9740.8%

**Analysis:**

*   **MRI:**  A Market Risk Indicator of 0.8 suggests a medium level of investment recommendation.
*   **RSI:** The RSI of 27.56 indicates that the stock is approaching oversold conditions, which could suggest a potential buying opportunity.
*   **PPO:**  The PPO of -0.3152 suggests that the stock is bearish trend (but close to the zero point).
*   **Hybrid Signal:** The hybrid signal suggests a fully invested position, deemed "Very Safe" with a higher MRI (0.90), and a monthly investment strategy.
*   **Relative Divergence Change:** The positive change in relative divergence over the last 20 days indicates a recent short-term upward trend.
*   **Expected Return:** The extremely negative expected return (-9740.8%) is concerning. The high negative expected return casts strong doubts on the long-term outlook.

**4. Recent News & Significant Events (Yahoo Finance):**

*   **[2025-12-13] Forget Teladoc and Buy This Healthcare Stock Instead - The Motley Fool:** Negative sentiment, suggesting alternatives.
*   **[2026-01-03] How the (TDOC) price action is used to our Advantage (TDOC:CA) - Stock Traders Daily:** Potentially positive, but vague; depends on the content's strategy.
*   **[2025-12-22] Why Teladoc (TDOC) Stock Is Up Today - Yahoo Finance:** Indicates a short-term positive movement.
*   **[2025-12-24] HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling? - Zacks Investment Research:** Suggests a comparison, possibly highlighting weaknesses.
*   **[2025-10-06] Teladoc (TDOC) Stock Drops Despite Market Gains: Important Facts to Note - Nasdaq:** Negative performance despite broader market trends.
*   **[2025-12-20] Is Teladoc a Bargain After a 96% Slide and DCF Suggesting Major Upside? - simplywall.st:**  Suggests the stock *may* be undervalued after a significant drop, but requires further investigation.

**Analysis:** The news headlines paint a mixed picture. There's negativity regarding alternative healthcare stocks and underperformance, but also potential for short-term gains and suggestions of being undervalued.

**4-2. Analyst Opinions:**

*   **Analyst Consensus:**
    *   Key: None
    *   Mean (1=StrongBuy~5=Sell): - (~-)
    *   Opinions: 22
    *   Target Price (avg/high/low): 9.18 / 12.00 / 7.00
    *   Recent Rating Changes: No Data

**Analysis:** The analyst target price is at an average of $9.18, indicating potential upside from the current price. There's no recommendation consensus nor are there are recent rating changes listed.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|--------|-------------|
| 2025-10-30 | -0.28 | 0.63 B$   |
| 2025-07-30 | -0.19 | 0.63 B$   |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2025-10-30 | -0.19 | 0.64 B$   |

**Analysis:**

*   **EPS:**  Teladoc has been consistently reporting negative EPS, indicating a lack of profitability.
*   **Revenue:** Revenue has been relatively flat, and is trending slightly downward.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.63B    | 70.12%       |
| 2025-06-30   | $0.63B    | 69.85%       |
| 2025-03-31   | $0.63B    | 68.73%       |
| 2024-12-31   | $0.64B    | 70.50%       |
| 2024-09-30   | $0.64B    | 71.94%       |

**Analysis:**  Revenue is flat at ~0.63B. Despite the high profit margin reported, the EPS is negative, so there is an item missing that is reducing the profit margins.

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-09-30   | $1.39B   | -3.56%  |
| 2025-06-30   | $1.42B   | -2.30%  |
| 2025-03-31   | $1.43B   | -6.52%  |
| 2024-12-31   | $1.49B   | -3.25%  |
| 2024-09-30   | $1.51B   | -2.21%  |

**Analysis:** Equity is trending downward, indicating a shrinking book value.  ROE is consistently negative, further confirming the company's lack of profitability.

**7. Comprehensive Analysis (Summary)**

TDOC has significantly underperformed the S&P 500. While the RSI suggests the stock is approaching oversold territory and there's been a short-term positive divergence, the company faces substantial challenges:

*   **Poor Financial Performance:** Consistently negative EPS and ROE, flat revenue.
*   **High Volatility:** Demonstrated by high MDD and beta values in the past.
*   **Negative Sentiment:** News headlines suggest alternatives and highlight underperformance.
*   **Questionable Long-Term Outlook:** The extremely negative expected return indicates significant risk and a highly uncertain future.

**Conclusion:**

Based on the provided data, investing in TDOC appears risky. Despite potential short-term gains due to oversold conditions, the company's poor financial performance, negative sentiment, and questionable long-term outlook raise serious concerns. While analysts have a target price that is higher, there is no consensus and it might not be reliable. The overall picture suggests caution and a need for significant due diligence before considering an investment in TDOC.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.